Website Agenda : 2021 Phage Futures Global

Name	Speakers
Case studies using phage therapy to treat prosthetic joint infections at the Mayo Clinic	Gina Suh - Mayo Clinic
Considerations for liquid formulations & solid dosage forms	Danish Malik - University of Loughborough
CRISPR-Cas3-enhanced bacteriophages to target Escherichia coli bacteria causing urinary tract infections	David Ousterout - Locus Biosciences
Phage application in food safety	Joël van Mierlo - Micreos
Phage-based COVID-19 vaccine development	Subhendu Basu - Adaptive Phage Therapeutics
Phage-based vaccine development in oncology	Anupuma Hoey - Sensei Biotherapeutics
Phage therapy for biofilm related multidrug resistant wound infections	Biswajit Biswas - US Naval Medical Research
Phage therapy for Inflammatory Bowel Disease & Primary Sclerosing Cholangitis	Sailaja Puttagunta - BiomX
Phage therapy for treating cholera	Mimi Yen - PhagePro Inc.
Research into the role of the virome in the human microbiome	David Pride - UC San Diego Health
Synthetic phages in livestock health	Henrik Almblad - Cytophage Technologies Inc.
The engineered Gardnerella endolysin PM-477 as a potential breakthrough microbiome therapy for recurrent bacterial vaginosis	Lorenzo Corsini - Managing Director
Treating lung infections with phage therapy	Paul Turner - Yale University
ε2-phages and the cocktail PM-399: non-wild-type, non-GMO phages with vastly improved pharmaceutical properties against S. aureus	Lorenzo Corsini - Managing Director

Name	Speakers
9:00 AM - 9:15 AM (EST)
OPENING REMARKS: Overview of the latest progressions in the clinical landscape for phage-based application	Richard Alm - CARB-X
9:20 AM - 10:00 AM (EST)
PANEL: Pharma Insights: Designing phage-based clinical trials to prove efficacy.	Henry ‘Chip’ Chambers - UC San Francisco Todd Black - Merck & Co. Bob Blasdel - Vésale Pharmaceutica Kristin Wannerberger - Ferring Pharmaceuticals
11:30 AM - 12:10 PM (EST)
PANEL: Translating in vitro into in vivo: Understanding the pharmacology of bacteriophages	Paul Turner - Yale University Bob Blasdel - Vésale Pharmaceutica Martha Clokie - University of Leicester Jessica Sacher - Phage Directory
12:25 PM - 12:50 PM (EST)
PRESENTATION: From initial phage candidate to manufacturing Clinical Trial Material	Frenk Smrekar - Jafral Barbara Hubad - Jafral
1:00 PM - 1:30 PM (EST)
PANEL: To Build or To Buy: In-house or Out-source?	Nick Conley - Locus Biosciences Frenk Smrekar - Jafral Michael Koeris - NIH

Name	Speakers
9:00 AM - 9:40 AM (EST)
PANEL: Creating a robust marketinfrastructure for phage therapy	Peter Beyer - World Health Organization (WHO) Michael Koeris - NIH Carrie Fur - Bacteriophage & Drug Development Consultants
9:50 AM - 10:40 AM (EST)
PANEL: Securing financial support from the public, private & philanthropic sectors to continue innovation in phage-based applications	Richard Alm - CARB-X Joseph Campbell - ex-NIH Greg Merril - Adaptive Phage Therapeutics
10:45 AM - 11:25 AM (EST)
PANEL: Beyond the flask: phage amplification at scale	Adam Ostrowski - Cellexus International Ltd Teresa Duarte - VectorB2B Jonathan Kotula - Felix Biotechnology Rodrigo García González - Instituto de Biología, Pontificia Universidad Católica de Valparaíso Manuel Garrido - TechnoPhage
12:35 PM - 1:15 PM (EST)
TOWNHALL: Success or failure in compassionate use; why does phage therapy not always succeed?	Shawna McCallin - Balgrist University Hospital Benjamin Chan - Yale University Gina Suh - Mayo Clinic Graham Hatfull - University of Pittsburgh Jonathon Iredell - Westmead Institute for Medical Research

9:00 AM - 10:00 AM (EST)
1: US Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act and its implications for phage therapy	Carrie Fur - Bacteriophage & Drug Development Consultants
2: International regulatory requirements for the approval of phage therapeutics	Cara Fiore - FDA
3: US Regulatory Pathway for Phages as Veterinary Drugs	Joshua Hayes - US Food and Drug Administration, Center for Veterinary Medicine
10:15 AM - 10:45 AM (EST)
LIVE Q & A for US Regulatory Pathways for Phage Therapeutics	Carrie Fur - Bacteriophage & Drug Development Consultants Cara Fiore - FDA Joshua Hayes - US Food and Drug Administration, Center for Veterinary Medicine
11:15 AM - 12:00 PM (EST)
PANEL: Concluding Thoughts from the Phage Futures Congress 2021	Richard Alm - CARB-X Ella Balsala - Virginia Commonwealth University Bob Blasdel - Vésale Pharmaceutica Benjamin Chan - Yale University Lorenzo Corsini - Managing Director Cara Fiore - FDA Carrie Fur - Bacteriophage & Drug Development Consultants Graham Hatfull - University of Pittsburgh Danish Malik - University of Loughborough Shawna McCallin - Balgrist University Hospital Adam Ostrowski - Cellexus International Ltd Frenk Smrekar - Jafral

Dr Richard Alm
CARB-X
Director of Alliances & Consultant - WHO

Dr. Henrik Almblad
Cytophage Technologies Inc.
Staff Scientist

Ella Balsala
Virginia Commonwealth University
Patient Advocacy & Engagement Consultant, Phage Therapy Recipient

Dr Subhendu Basu
Adaptive Phage Therapeutics
COO

Dr Peter Beyer
World Health Organization (WHO)
Senior Advisor

Dr Biswajit Biswas
US Naval Medical Research
Chief of Phage Laboratory, Biological Defense Research Directorate

Dr Todd Black
Merck & Co.
Executive Director of Infectious Diseases

Dr Bob Blasdel
Vésale Pharmaceutica
Research Director

Dr Joseph Campbell
ex-NIH
Program Officer

Dr Henry ‘Chip’ Chambers
UC San Francisco
Professor of Medicine, Emeritus & Principal Investigator, ARLG

Dr Benjamin Chan
Yale University
Associate Research Scientist

Professor Martha Clokie
University of Leicester
Professor of Microbiology

Dr Nick Conley
Locus Biosciences
VP, Technology, R&D

Dr Lorenzo Corsini
Managing Director
BioNTech R&D (Austria)

Mrs Teresa Duarte
VectorB2B
Head of CMC

Dr Xavier Duportet
Eligo Biosciences
CEO & Co-Founder

Dr Cara Fiore
FDA
Microbiologist

Dr Carrie Fur
Bacteriophage & Drug Development Consultants
Chief Executive Officer

Dr Rodrigo García González
Instituto de Biología, Pontificia Universidad Católica de Valparaíso
Phd Student - Laboratorio de Microbiología

Dr Manuel Garrido
TechnoPhage
Production Specialist

Dr Steven Hagens
Micreos Pharma
Executive Assistant to the CSO

Dr Graham Hatfull
University of Pittsburgh
Eberly Family Professor of Biotechnology, HHMI Professor

Dr. Joshua Hayes
US Food and Drug Administration, Center for Veterinary Medicine
Microbiologist

Michael J Higgins
Ladenburg Thalmann
MD Biopharmaceuticals Equity Research

Anupuma Hoey
Sensei Biotherapeutics
CBO

Dr Barbara Hubad
Jafral
COO

Dr Jonathon Iredell
Westmead Institute for Medical Research
Director of Centre for Infectious Diseases & Microbiology

Dr Michael Koeris
NIH
Portfolio Executive, NIH RADx COVID-19 Response Program

Dr Jonathan Kotula
Felix Biotechnology
Head of Science

Dr Timothy Lu
MIT
Associate Professor of Biological Engineering, Synthetic Biology Center

Dr Danish Malik
University of Loughborough
Professor

Dr Shawna McCallin
Balgrist University Hospital
Clinical Coordinator

Greg Merril
Adaptive Phage Therapeutics
CEO

Dr Tobi Nagel
Phages for Global Health
Founder & President

Dr Adam Ostrowski
Cellexus International Ltd
Technical Application Specialist

Dr David Ousterout
Locus Biosciences
CSO & Co-Founder

Dr David Pride
UC San Diego Health
Infectious Disease Specialist

Dr Sailaja Puttagunta
BiomX
CMO

Dr. Jessica Sacher
Phage Directory
Co-founder

Dr Frenk Smrekar
Jafral
Co-Founder & CEO

Dr Gina Suh
Mayo Clinic
Managing Director of Infectious Diseases

Dr Paul Turner
Yale University
Professor of Ecology & Evolutionary Biology

Dr Joël van Mierlo
Micreos
R&D Manager for Micreos Food Safety

Dr Kristin Wannerberger
Ferring Pharmaceuticals
Director and R&D Alliance Manager

Dr. Mimi Yen
PhagePro Inc.
Co-founder & CEO

PHAGE FUTURES CONGRESS

EVENT AGENDA

MEET OUR SPEAKERS